多西他赛联合表阿霉素4周期新辅助化疗方案治疗乳腺癌59例临床观察

Clinical Study Of ET 4 Cycle Program Neoadjuvant Chemotherapy Using Docetaxel and Pharmorubicin For 59 Patients With Breast Cancer

观察多西他赛联合表阿霉素（ET）4周期在乳腺癌的新辅助治疗中的疗效及毒副反应。2006年1月至2007年2月，共纳入的Ⅱ～Ⅲ期女性乳腺癌患者59例。均行4周期的ET方案新辅助化疗，化疗结束后评价疗效和毒副反应。结果显示，临床总有效率（RR为CR＋PR）为91．5％（54／59），其中临床完全缓解（CR）15例，部分缓解（PR）39例，稳定（SD）5例，进展（PD）0例。故多西他赛联合表阿霉素4周期方案在乳腺癌的新辅助化疗中疗效肯定，毒副反应可耐受。

We report on the efficacy and toxicity of ET 4 cycle program neoadjuvant chemotherapy using docetaxel and pharmorubicin. From January 2006 to February 2007,59 patients affected by breast cancer were treated with ET 4 cycle program neoadjuvant chemotherapy.We evaluate the efficacy and toxicity. The result shows that,the clinical effective rate was 91.5% （54/59）, in which CR 15 cases,PR 39 eases,SD 5 ease and PD 0 case. And the toxicity can be tolerated.So, ET 4 cycle program neoadjuvant chemotherapy in breast cancer is effective and the toxicity can be tolerated.